Ixaka   Report issue

For profit Phase 3
Founded: London United Kingdom (2015)

Organization Overview

First Clinical Trial
2017
NCT03111238
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now